Mon. Oct 20th, 2025

Ryan Confer Discusses Genprex’s Future in Diabetes and Oncology NASDAQ: GNPX

ByCoinz

October 28, 2024 , ,
In an in-depth conversation with Ryan Confer, CEO of Genprex (GNPX), we explored the company’s dynamic pipeline, including lead candidates like Reqorsa® Gene Therapy for lung cancer and GPX-002 for diabetes. Ryan shared insights into their impressive $100 million funding raise, detailing the company's strategic goals for the upcoming year. He highlighted ambitious milestones around partnerships and collaborations that are propelling Genprex forward in both oncology and diabetes. We dove into the technical aspects of Genprex's innovative therapies, discussing how each drug functions uniquely to target challenging diseases and how these therapies stand out amid industry competition. Ryan also shared his vision for when these therapies could reach the market, painting a clear picture of where Genprex sees itself in the future and how they plan to impact patient lives on a global scale.
This content is for Future 1% Membership members only.


Join Now
Log In


Listen to the Free Version of Marathon Money

Listen on Spotify


Listen on Apple Podcasts

These are publicly available episodes that anyone can access on Spotify or Apple Podcasts.
Exclusive Content: Premium content only available to members who join. It offers additional insights, interviews, or behind-the-scenes information not found in the free versions.
Already a member? Log in here

Discover more from Marathon Money +

Subscribe to get the latest posts sent to your email.

ByCoinz

Discover more from Marathon Money +

Subscribe now to keep reading and get access to the full archive.

Continue reading